Glaukos Corporation

Dose Medical Corporation

Ev3 Endovascular, Inc.

Endicor Medical, Inc.

Covidien LP

Baxter International Inc.

Edwards Lifesciences Corporation

Camino Neurocare, Inc.

Harold Alexander Heitzmann

David S Haffner

Thomas W Burns

Kenneth Martin Curry

David Applegate

Todd N Fjield

Richard A Hill

Bruce D Stambaugh

Paul Taylor

Rafael Pintor

John S Honeycutt

Bradley Steven Culbert

Bruce Nogales

Wayne Arthur Noda

Jeffrey S Dove

John T Armstrong

John D Richert

Ann Yadlowsky

Michael LeRoy Gelvin

Morgan T McKeown

Lauralan T Grisoni

Ken Curry

Vanessa Tasso

John A Frazier

George Francis Sutton, Iii

Kenneth M Curry

Morgan T Mckeown

Ann B Yadlowsky

Michael Le Roy Gelvin

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allows for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Drug eluting ocular implants

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Implants with controlled drug delivery features and methods of using same

Controlled drug delivery ocular implants and methods of using same

Drug eluting ocular implant

Drug eluting ocular implants and methods of treating an ocular disorder

Drug eluting ocular implant and method of treating an ocular disorder

Devices and methods for treating intraocular pressure are disclosed. The devices include shunts for draining aqueous humor from the anterior chamber to the uveoscleral outflow pathway, including the supraciliary space and the suprachoroidal space. The shunts are preferably implanted by ab interno procedures.

Uveoscleral shunt and methods for implanting same

Certain aspects relate to drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye. In several embodiments, the devices are capable of controlled release of two or more drugs, the release of each drug into a different ocular space (e.g., an ocular compartment versus an ocular fluid outflow pathway).

Drug delivery implants with bi-directional delivery capacity

An implantable intraocular physiological sensor for measuring intraocular pressure, glucose concentration in the aqueous humor, and other physiological characteristics. The implantable intraocular physiological sensor may be at least partially powered by a fuel cell, such as an electrochemical glucose fuel cell. The implantable intraocular physiological sensor may wirelessly transmit measurements to an external device. In addition, the implantable intraocular physiological sensor may incorporate aqueous drainage and/or drug delivery features.

Intraocular physiological sensor

An ocular implant configured for implantation into the eye of a subject comprising an elongate outer shell (), an internal plug () including a hydrogel and a drug reservoir including a drug () wherein the drug is configured to pass through at least a portion of the internal plug to control elution of the drug through the outer shell. The implant is made of biodegradable materials.

Bioresorbable ocular drug delivery device

Growing community of inventors

Irvine, CA, United States of America

Harold Alexander Heitzmann